View in EDS HTML Full Text PDF Full Text

Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.

Saved in:
Bibliographic Details
Title: Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.
Authors: Strati P; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pstrati@mdanderson.org., Feng L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Westin JR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Nair R; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fayad LE; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rodriguez MA; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chihara D; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Malpica L; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Henderson J; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gallardo M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Rivera M; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang I; BostonGene, Corp, Waltham, MA, USA., Bolshakova A; BostonGene, Corp, Waltham, MA, USA., Radko A; BostonGene, Corp, Waltham, MA, USA., Kurtz D; Foresight Diagnostics Inc, Boulder, CO, USA., Alig SK; Department of Internal Medicine III, Ludwig-Maximilian-University (LMU) Hospital, Munich, Germany., Flowers CR; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alizadeh AA; Stanford University School of Medicine, Stanford, CA, USA., Neelapu SS; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Source: Nature communications [Nat Commun] 2025 Aug 07; Vol. 16 (1), pp. 7300. Date of Electronic Publication: 2025 Aug 07.
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40775236
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Strati+P%22">Strati P</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. pstrati@mdanderson.org.<br /><searchLink fieldCode="AU" term="%22Feng+L%22">Feng L</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Westin+JR%22">Westin JR</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Nair+R%22">Nair R</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Fayad+LE%22">Fayad LE</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Rodriguez+MA%22">Rodriguez MA</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Chihara+D%22">Chihara D</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Malpica+L%22">Malpica L</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Henderson+J%22">Henderson J</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Gallardo+M%22">Gallardo M</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Rivera+M%22">Rivera M</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Wang+I%22">Wang I</searchLink>; BostonGene, Corp, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bolshakova+A%22">Bolshakova A</searchLink>; BostonGene, Corp, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Radko+A%22">Radko A</searchLink>; BostonGene, Corp, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kurtz+D%22">Kurtz D</searchLink>; Foresight Diagnostics Inc, Boulder, CO, USA.<br /><searchLink fieldCode="AU" term="%22Alig+SK%22">Alig SK</searchLink>; Department of Internal Medicine III, Ludwig-Maximilian-University (LMU) Hospital, Munich, Germany.<br /><searchLink fieldCode="AU" term="%22Flowers+CR%22">Flowers CR</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Alizadeh+AA%22">Alizadeh AA</searchLink>; Stanford University School of Medicine, Stanford, CA, USA.<br /><searchLink fieldCode="AU" term="%22Neelapu+SS%22">Neelapu SS</searchLink>; Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101528555%22">Nature communications</searchLink> [Nat Commun] 2025 Aug 07; Vol. 16 (1), pp. 7300. <i>Date of Electronic Publication: </i>2025 Aug 07.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101528555 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2041-1723 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220411723%22">20411723 </searchLink><i>NLM ISO Abbreviation: </i>Nat Commun <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40775236
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41467-025-62509-z
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 7300
    Titles:
      – TitleFull: Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Strati P
      – PersonEntity:
          Name:
            NameFull: Feng L
      – PersonEntity:
          Name:
            NameFull: Westin JR
      – PersonEntity:
          Name:
            NameFull: Nair R
      – PersonEntity:
          Name:
            NameFull: Fayad LE
      – PersonEntity:
          Name:
            NameFull: Rodriguez MA
      – PersonEntity:
          Name:
            NameFull: Chihara D
      – PersonEntity:
          Name:
            NameFull: Malpica L
      – PersonEntity:
          Name:
            NameFull: Henderson J
      – PersonEntity:
          Name:
            NameFull: Gallardo M
      – PersonEntity:
          Name:
            NameFull: Rivera M
      – PersonEntity:
          Name:
            NameFull: Wang I
      – PersonEntity:
          Name:
            NameFull: Bolshakova A
      – PersonEntity:
          Name:
            NameFull: Radko A
      – PersonEntity:
          Name:
            NameFull: Kurtz D
      – PersonEntity:
          Name:
            NameFull: Alig SK
      – PersonEntity:
          Name:
            NameFull: Flowers CR
      – PersonEntity:
          Name:
            NameFull: Alizadeh AA
      – PersonEntity:
          Name:
            NameFull: Neelapu SS
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 08
              Text: 2025 Aug 07
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2041-1723
          Numbering:
            – Type: volume
              Value: 16
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Nature communications
              Type: main
ResultId 1